NCT06648434 - MK2 Inhibitor in Combination With mFOLFIRINOX for Untreated Metastatic Pancreatic Ductal Adenocarcinoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 15, 2025

Primary Completion Date

June 30, 2027

Study Completion Date

May 31, 2030

Conditions

Metastatic Pancreatic Ductal AdenocarcinomaPancreatic CancerCancer of the Pancreas

Interventions

DRUG

Zunsemetinib

Patients should take zunsemetinib approximately 12 hours apart (if twice daily dosing) or 24 hours apart (if once daily dosing) at the same time(s) every day, with 8 oz of water.

DRUG

mFOLFIRINOX

Includes oxaliplatin, irinotecan, leucovorin, and 5-FU.

Trial Locations (1)

63110

RECRUITING

Washington University School of Medicine, St Louis